Ozmosi | Aminocaproic acid Drug Profile
Drug Profile
Using advanced filters...
Advanced Search [+]

Aminocaproic acid

Alternative Names: aminocaproic acid, amicar, epsilon-aminocaproic acid, aminocaproic, e-aminocaproic acid, aminocaproic acid in plastic container
Clinical Status: Inactive
Latest Update: 2026-06-12
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: Plasmin Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous, Oral

FDA Designation: *

Approval Status: Approved

Approved Countries: Argentina | Bangladesh | Brazil | Canada | China | Dominican Republic | Ecuador | Greece | Hong Kong | Hungary | India | Ireland | Italy | Korea | New Zealand | Portugal | Russia | Taiwan | Ukraine | United States | Uruguay | Venezuela | Vietnam

Approved Indications: None

Company: None
Company Location:
Company Founding Year: None
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated